Altaviva
Medtronic Neuromodulation · Decision date Mar 26, 2026
What did the FDA approve?
FDA records P240011/S011 as a supplement to PMA P240011, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Mar 26, 2026.
FDA approval order statement
approval for several administrative changes to the protocol and for Medtronic Neuromodulation to provide the commercial Altaviva system at no cost to study sites
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Mar 26, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P240011/S011
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Neuromodulation
- Product code
- QPT
- Decision code
- APPR
- Decision date
- Mar 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, tibial, electrical, implantable, for urinary incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- QPT
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240011 · Original PMA
Medtronic Altaviva System
P240011/S001 · Related supplement
Altaviva Implantable Neurostimulator
P240011/S002 · Related supplement
Altaviva Implantable Neurostimulator
P240011/S004 · Related supplement
Medtronic Altaviva System
P240011/S007 · Related supplement
Altaviva Tibial Neuromodulation System (Altaviva P7850N)
P240011/S006 · Related supplement
Altaviva Model P7850N
P240011/S011 received
Application receipt date recorded by FDA.
P240011/S011 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P240011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240011
Explore the linked device profile
Other records with product code QPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
eCoin Peripheral NeurostimulatorP200036/S012 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Sep 9, 2026 | FDA |
eCoin Peripheral NeurostimulatorP200036/S011 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jul 20, 2026 | FDA |
eCoin Peripheral NeurostimulatorP200036/S010 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Mar 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave. NE, Ms Rce480, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P240011/S011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records







